PNC Financial Services Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

PNC Financial Services Group’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$18.4K	Buy	632 +226	+56%	+$5.99K	﹤0.01%	3905
2026 Q2	$7.29K	Buy	406 +123	+43%	+$1.9K	﹤0.01%	4236
2026 Q1	$3.93K	Sell	283 -155	-35%	-$2.18K	﹤0.01%	4369
2025 Q4	$5.29K	Sell	438 -47	-10%	-$638	﹤0.01%	4218
2025 Q3	$6.59K	Buy	485 +432	+815%	+$4.07K	﹤0.01%	4104
2025 Q2	$340	Hold	53	–	–	﹤0.01%	4735
2025 Q1	$188	Hold	53	–	–	﹤0.01%	4785
2024 Q4	$200	Sell	53 -43	-45%	-$202	﹤0.01%	4650
2024 Q3	$311	Hold	96	–	–	﹤0.01%	4622
2024 Q2	$182	Sell	96 -118	-55%	-$229	﹤0.01%	4680
2024 Q1	$608	Buy	214 +18	+9%	+$235	﹤0.01%	4468
2023 Q4	$2.88K	Buy	+196	New	+$3K	﹤0.01%	4100
2023 Q2	–	Sell	-100	Closed	-$2.93K	–	4729
2023 Q1	$2.93K	Buy	+100	New	+$3.47K	﹤0.01%	4208

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.3B AUM 33.78% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

PNC Financial Services Group's AMLX Position: Q3 2026 in Review

PNC Financial Services Group increased its Amylyx Pharmaceuticals (AMLX) stake by 56% in Q3 2026, buying an estimated $5.99K and bringing the position to 632 shares worth $18.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3905.

PNC Financial Services Group first reported a position in AMLX in Q1 2023 and has held it in 13 quarters since. 88 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

PNC Financial Services Group held 632 shares of Amylyx Pharmaceuticals worth $18.4K as of Q3 2026.
PNC Financial Services Group bought 226 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $5.99K.
Amylyx Pharmaceuticals made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #3905 holding.
PNC Financial Services Group first reported a position in Amylyx Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
88 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.